{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:55:21Z","timestamp":1756896921079,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Peripheral T\u2010cell lymphomas (PTCLs) are a heterogeneous group of neoplasms characterized by a poor prognosis. Histone deacetylase (HDAC) inhibitors have emerged as novel therapeutic agents for PTCLs. In this study, we aimed to explore the immunomodulatory effect of the HDAC inhibitor chidamide on circulating PD-1(+) cells from patients with PTCL, as well as its correlation with treatment response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled newly diagnosed patients with PTCLs treated with a combination of chidamide and chemotherapy. Gene expression profile analysis was performed on peripheral blood PD-1(+) cells, both at baseline and at the end of treatment. A list of differentially expressed genes (DEGs) was identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to annotate the biological implications of the DEGs. A gene concept network was constructed to identify the key DEGs for further PCR verification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 302 DEGs were identified in the complete remission (CR) group, including 162 upregulated and 140 downregulated genes. In contrast, only 12 DEGs were identified in the non-CR group. GO analysis revealed that these upregulated DEGs were mainly involved in chemokine activity, cell chemotaxis, and cellular response to interleukin-1 and interferon-\u03b3. Furthermore, KEGG pathway analysis showed that these DEGs were enriched in cytokine-cytokine receptor interaction and chemokine signaling pathways. The innate immune signaling pathways, including the Toll-like and NOD-like receptor signaling pathways, were also influenced. The gene concept network revealed that the key upregulated genes belonged to the C-C chemokine family.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results showed that chidamide treatment notably enhanced the expression of genes associated with chemokine activity and chemotaxis function of circulating PD-1(+) cells. By recruiting immune cells and improving the innate immune function of PD-1(+) cells, chidamide may reshape the tumor microenvironment to an anti-tumor phenotype and synergize with checkpoint inhibitors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.682436","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T06:29:03Z","timestamp":1622528943000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL"],"prefix":"10.3389","volume":"11","author":[{"given":"Chong","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoxuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3037","article-title":"Improving Survival of 3760 Patients With Lymphoma: Experience of an Academic Center Over Two Decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10301","article-title":"Chidamide, a Histone Deacetylase Inhibitor, Induces Growth Arrest and Apoptosis in Multiple Myeloma Cells in a Caspase-Dependent Manner","volume":"18","author":"Yuan","year":"2019","journal-title":"Oncol Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC Inhibition Reduces Breast Tumours and Metastases Through Anti-Tumour Macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/jca.44622","article-title":"HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment","volume":"11","author":"Kim","year":"2020","journal-title":"J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2097","article-title":"Circulating PD-1 (+) Cells may Participate in Immune Evasion in Peripheral T-Cell Lymphoma and Chidamide Enhance the Antitumor Activity of PD-1 (+) Cells","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.60.3.365","article-title":"Human Recombinant Monocyte Chemotactic Protein and Other C-C Chemokines Bind and Induce Directional Migration of Dendritic Cells In Vitro","volume":"60","author":"Xu","year":"1996","journal-title":"J Leukoc Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy","volume":"10","author":"Mollica Poeta","year":"2019","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of Lymphoid Neoplasms in China: Analysis of 4,638 Cases According to the World Health Organization Classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of Chidamide for Peripheral T-Cell Lymphoma, the First Orphan Drug Approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 Trial of Romidepsin in Patients With Peripheral T-Cell Lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II Belief (CLN-19) Study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results From a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-Cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.10.013","article-title":"Histone Deacetylases Positively Regulate Transcription Through the Elongation Machinery","volume":"13","author":"Greer","year":"2015","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of Resistance to PD-1 and PD-L1 Blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"B23","first-page":"39","article-title":"Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer\/T Cell Lymphoma, Nasal Type (R\/r-ENKTL): Preliminary Results From a Prospective, Multicenter, Single-Arm, Phase Ib\/II Trial (SCENT)","volume-title":"Blood","author":"Gao","year":"2020"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.682436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T06:29:06Z","timestamp":1622528946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.682436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":23,"alternative-id":["10.3389\/fonc.2021.682436"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.682436","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"article-number":"682436"}}